PAK1 and Down syndrome: Morphometric analyses revealed that inhibiting PAK1 activity with FRAX486 (a non‐selective PAK1 inhibitor) enhanced neurite outgrowth, increased synaptic complexity and the number of intersections per Sholl ring, promoted the formation of new processes, and stimulated the loss of processes in a cellular model of Down syndrome.67